Brands
YSTV
Discover
Events
Newsletter
More

Follow Us

twitterfacebookinstagramyoutube
Yourstory

Brands

Resources

Stories

General

In-Depth

Announcement

Reports

News

Funding

Startup Sectors

Women in tech

Sportstech

Agritech

E-Commerce

Education

Lifestyle

Entertainment

Art & Culture

Travel & Leisure

Curtain Raiser

Wine and Food

Videos

ADVERTISEMENT
Advertise with us

Serum Institute to acquire 20% stake in IntegriMedical

The innovative drug delivery solution aims to alleviate pain during administration, providing needle-phobic patients with a stress-free experience.

Serum Institute to acquire 20% stake in IntegriMedical

Friday May 17, 2024 , 2 min Read

Vaccine manufacturer Serum Institute of India (SII) is acquiring a 20% stake in IntegriMedical to advance the needle-free injection system technology.

IntegriMedical has developed a US patented needle-free injection system (N-FIS) that utilises high-velocity jet stream using mechanical power to effectively and consistently administer biologics and drugs, SII said in a statement.

The company, however, did not disclose the financial details of the transaction.

"IntegriMedical's N-FIS represents a significant advancement in drug delivery, and we envision a needle-free solution to deliver vaccines. We believe this could potentially revolutionise the way we administer vaccines, making the process more comfortable for patients and healthcare professionals," said SII CEO Adar Poonawalla.

IntegriMedical's N-FIS has received regulatory approvals from the Central Drugs Standard Control Organisation, CE (European regulatory approval) MDSAP (Medical Device Single Audit Program, Australia), and is ISO 13485 certified, SII said in the statement.

"Additionally, the technology is patented in the United States," it added.

"This investment is a testament to the potential of our needle-free Injections System technology and its ability to revolutionise drug delivery. SII's expertise in vaccine manufacturing and global distribution will be invaluable as we work towards making our technology more widely accessible to patients worldwide," said IntegriMedical Managing Director Sarvesh Mutha.

N-FIS will be available in the Indian private market, offering patients and healthcare providers an alternative to traditional needle-based injections, said SII.

The technology's advantages include the elimination of needle phobia, alleviation of pain during administration, convenience of use, and prevention of needle-stick injuries and cross-contamination, it added.


Edited by Swetha Kannan